目的:考察左乙拉西坦对癫痫患儿性激素和甲状腺激素的影响,并评价其安全性.方法:选择2013年7月-2015年2月南通大学附属医院(以下简称"我院")初诊为癫痫的患儿22例,设为观察组;选择同期于我院行健康体检的儿童17例,设为对照组.观察组患儿给予左乙拉西坦片,起始剂量为10 mg/kg,每1～2周增加10 mg/(kg·d)[目标剂量为30～40 mg/(kg·d)],疗程为12个月.观察对照组儿童用药前和观察组患儿用药前以及用药后3、6、12个月的性激素[促卵泡生成素、促黄体生成素、垂体泌乳素、孕酮、睾酮、雌二醇]和甲状腺激素[总三碘甲状腺原氨酸(TT3)、总甲状腺素(TT4)、游离三碘甲状腺原氨酸(FT3)、游离甲状腺素(FT4)、促甲状腺激素(TSH)]水平,记录观察组患儿不良反应发生情况.结果:用药前,两组受试者的性激素、甲状腺激素水平比较,差异均无统计学意义(P>0.05).用药后3、6、12个月,观察组患儿性激素水平与用药前比较,差异均无统计学意义(P>0.05);用药后3、6个月,观察组患儿甲状腺激素水平与用药前比较,差异均无统计学意义(P>0.05);用药后12个月,TT3、TT4、FT4、TSH水平与用药前比较,差异均无统计学意义(P>0.05),而FT3水平较用药前显著升高,差异有统计学意义(P0.05). Three,six,twelve months after medication,there was no statistical significance in the levels of sex hormone in observation group compared to before medication(P>0.05). Three,six months after medication,there was no statis-tical significance in the levels of thyroid hormone in observation group compared to before medication (P>0.05). Twelve months after medication,there was no statistical significance in the levels of TT3,TT4,FT4 or TSH compared to before medi-cation(P>0.05);the level of FT3 was increased significantly,with statistical significance(P<0.05). Two cases of observation group suffered from ADR (9.1％). Without special treatment,the symptoms all disappeared 1-2 weeks later. CONCLUSIONS:Levetiracetam can be used for pediatric epilepsy and has no significant effects on the level of sex hormone,but increases the lev-el of FT3.
展开▼
